← Back to Clinical Trials
Recruiting NCT06479616

NCT06479616 A Long-term Follow-up Study in Participants Who Received CS-101

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06479616
Status Recruiting
Phase —
Sponsor Children's Hospital of Fudan University
Condition Beta-Thalassemia
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2024-06-18
Primary Completion 2026-12

Trial Parameters

Condition Beta-Thalassemia
Sponsor Children's Hospital of Fudan University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 5
Sex ALL
Min Age 3 Years
Max Age 17 Years
Start Date 2024-06-18
Completion 2026-12
Interventions
CS-101

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)

Eligibility Criteria

Inclusion Criteria: * Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form * Participants must have received CS-101 infusion in last IIT study Exclusion Criteria: * There are no exclusion criteria

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE BETA-THALASSEMIA TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology